Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides

Weihong Sun, Xiaofang Wei, Airong Niu, Xuezhen Ma, Jian-Jian Li, Daiqing Gao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Eukaryotic elongation factor-2 (eEF2) is overexpressed in many human cancers and is an attractive target for cancer immunotherapy. The eEF2 derived polypeptides have been shown to be able to induce cytotoxic T lymphocytes from healthy donor. Here, we demonstrate the evidence indicating that modification of a segment of peptides from wild type eEF2-derived immunogenic peptides is able to further enhance its capacity of inducing antigen-specific cytotoxic T lymphocytes (CTLs) against colon cancer cells. Using peptide-MHC binding algorithms, potential HLA-A2.1-restricted epitopes capable of inducing specific CD8+ CTLs were identified. By analyzing HLA-A2.1 affinity and immunogenicity, we further identified one novel immunogenic peptide, P739-747 (RLMEPIYLV), that elicited specific CTL responses in HLA-A2.1/Kb transgenic mice and culture with peripheral blood lymphocytes from colon cancer patients. Furthermore, replacing certain amino acids (at positions 1, 3, 7) within the P739-747 sequence improved the immunogenicity against eEF2. Several analogs containing the auxiliary HLA-A*0201 anchor residues were able to stably bind to HLA-A*0201 and enhance CTL responses compared with the native sequence; two of them showed increased anti-tumor effects during the adoptive immunotherapy in vivo. Thus, these results support that modified immunogenic analogs are promising candidates for peptide-based cancer vaccination and immunotherapy.

Original languageEnglish (US)
Pages (from-to)112-123
Number of pages12
JournalCancer Letters
Volume369
Issue number1
DOIs
StatePublished - Dec 1 2015

Fingerprint

Peptide Elongation Factor 2
Cytotoxic T-Lymphocytes
Colonic Neoplasms
Peptides
Immunotherapy
Neoplasms
Adoptive Immunotherapy
Transgenic Mice
Epitopes
Vaccination
Tissue Donors
Lymphocytes
Antigens
Amino Acids

Keywords

  • Adoptive immunotherapy
  • Colon cancer
  • CTL
  • Enhanced immunoresponse
  • HLA-A2.1-restricted
  • Modified epitope

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides. / Sun, Weihong; Wei, Xiaofang; Niu, Airong; Ma, Xuezhen; Li, Jian-Jian; Gao, Daiqing.

In: Cancer Letters, Vol. 369, No. 1, 01.12.2015, p. 112-123.

Research output: Contribution to journalArticle

Sun, Weihong ; Wei, Xiaofang ; Niu, Airong ; Ma, Xuezhen ; Li, Jian-Jian ; Gao, Daiqing. / Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides. In: Cancer Letters. 2015 ; Vol. 369, No. 1. pp. 112-123.
@article{53b2fb0581d848eabcdc8cd208f6b82d,
title = "Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides",
abstract = "Eukaryotic elongation factor-2 (eEF2) is overexpressed in many human cancers and is an attractive target for cancer immunotherapy. The eEF2 derived polypeptides have been shown to be able to induce cytotoxic T lymphocytes from healthy donor. Here, we demonstrate the evidence indicating that modification of a segment of peptides from wild type eEF2-derived immunogenic peptides is able to further enhance its capacity of inducing antigen-specific cytotoxic T lymphocytes (CTLs) against colon cancer cells. Using peptide-MHC binding algorithms, potential HLA-A2.1-restricted epitopes capable of inducing specific CD8+ CTLs were identified. By analyzing HLA-A2.1 affinity and immunogenicity, we further identified one novel immunogenic peptide, P739-747 (RLMEPIYLV), that elicited specific CTL responses in HLA-A2.1/Kb transgenic mice and culture with peripheral blood lymphocytes from colon cancer patients. Furthermore, replacing certain amino acids (at positions 1, 3, 7) within the P739-747 sequence improved the immunogenicity against eEF2. Several analogs containing the auxiliary HLA-A*0201 anchor residues were able to stably bind to HLA-A*0201 and enhance CTL responses compared with the native sequence; two of them showed increased anti-tumor effects during the adoptive immunotherapy in vivo. Thus, these results support that modified immunogenic analogs are promising candidates for peptide-based cancer vaccination and immunotherapy.",
keywords = "Adoptive immunotherapy, Colon cancer, CTL, Enhanced immunoresponse, HLA-A2.1-restricted, Modified epitope",
author = "Weihong Sun and Xiaofang Wei and Airong Niu and Xuezhen Ma and Jian-Jian Li and Daiqing Gao",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.canlet.2015.08.002",
language = "English (US)",
volume = "369",
pages = "112--123",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides

AU - Sun, Weihong

AU - Wei, Xiaofang

AU - Niu, Airong

AU - Ma, Xuezhen

AU - Li, Jian-Jian

AU - Gao, Daiqing

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Eukaryotic elongation factor-2 (eEF2) is overexpressed in many human cancers and is an attractive target for cancer immunotherapy. The eEF2 derived polypeptides have been shown to be able to induce cytotoxic T lymphocytes from healthy donor. Here, we demonstrate the evidence indicating that modification of a segment of peptides from wild type eEF2-derived immunogenic peptides is able to further enhance its capacity of inducing antigen-specific cytotoxic T lymphocytes (CTLs) against colon cancer cells. Using peptide-MHC binding algorithms, potential HLA-A2.1-restricted epitopes capable of inducing specific CD8+ CTLs were identified. By analyzing HLA-A2.1 affinity and immunogenicity, we further identified one novel immunogenic peptide, P739-747 (RLMEPIYLV), that elicited specific CTL responses in HLA-A2.1/Kb transgenic mice and culture with peripheral blood lymphocytes from colon cancer patients. Furthermore, replacing certain amino acids (at positions 1, 3, 7) within the P739-747 sequence improved the immunogenicity against eEF2. Several analogs containing the auxiliary HLA-A*0201 anchor residues were able to stably bind to HLA-A*0201 and enhance CTL responses compared with the native sequence; two of them showed increased anti-tumor effects during the adoptive immunotherapy in vivo. Thus, these results support that modified immunogenic analogs are promising candidates for peptide-based cancer vaccination and immunotherapy.

AB - Eukaryotic elongation factor-2 (eEF2) is overexpressed in many human cancers and is an attractive target for cancer immunotherapy. The eEF2 derived polypeptides have been shown to be able to induce cytotoxic T lymphocytes from healthy donor. Here, we demonstrate the evidence indicating that modification of a segment of peptides from wild type eEF2-derived immunogenic peptides is able to further enhance its capacity of inducing antigen-specific cytotoxic T lymphocytes (CTLs) against colon cancer cells. Using peptide-MHC binding algorithms, potential HLA-A2.1-restricted epitopes capable of inducing specific CD8+ CTLs were identified. By analyzing HLA-A2.1 affinity and immunogenicity, we further identified one novel immunogenic peptide, P739-747 (RLMEPIYLV), that elicited specific CTL responses in HLA-A2.1/Kb transgenic mice and culture with peripheral blood lymphocytes from colon cancer patients. Furthermore, replacing certain amino acids (at positions 1, 3, 7) within the P739-747 sequence improved the immunogenicity against eEF2. Several analogs containing the auxiliary HLA-A*0201 anchor residues were able to stably bind to HLA-A*0201 and enhance CTL responses compared with the native sequence; two of them showed increased anti-tumor effects during the adoptive immunotherapy in vivo. Thus, these results support that modified immunogenic analogs are promising candidates for peptide-based cancer vaccination and immunotherapy.

KW - Adoptive immunotherapy

KW - Colon cancer

KW - CTL

KW - Enhanced immunoresponse

KW - HLA-A2.1-restricted

KW - Modified epitope

UR - http://www.scopus.com/inward/record.url?scp=84943456027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943456027&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2015.08.002

DO - 10.1016/j.canlet.2015.08.002

M3 - Article

VL - 369

SP - 112

EP - 123

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -